SAB Biotherapeutics (NASDAQ:SABS) used an appearance at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference to outline its strategy in type 1 diabetes (T1D), emphasizing development of a fully human anti-thymocyte globulin (ATG) designed to preserve pancreatic beta cell function in newly diagnosed patients. Company focus and lead program Chief Executive Officer Sam Reich said SAB’s […]